Dr. Emily B. Tomasulo, D.O.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Philadelphia College of Osteopathic Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 211
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Philadelphia College of Osteopathic Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license OS022653 -
Internal Medicine Physician
PA license OS022653
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Penn Presbyterian Medical Center Philadelphia, PA
- Chester County Hospital West Chester, PA
- Pennsylvania Hospital Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 211
- Services billed
- 902
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 35 | 19 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 20 | 19 |
| Hospital discharge day management, 30 minutes or less | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 22 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Philadelphia, PA | 13 |
| Prednisone Other prescribers in Philadelphia, PA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 37 payments worth $14,748 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $4,398 |
|---|---|
| Genzyme Corporation | $3,247 |
| Genentech USA, Inc. | $3,054 |
| AbbVie Inc. | $2,819 |
| E.r. Squibb & Sons, L.l.c. | $710 |
| Genmab U.S., Inc. | $246 |
| Novartis Pharmaceuticals Corporation | $114 |
| Janssen Scientific Affairs, LLC | $68.87 |
| Consulting Fee | $11,220 |
|---|---|
| Food and Beverage | $1,357 |
| Travel and Lodging | $1,101 |
| Compensation for services other than consulting (speaking, faculty) | $1,070 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Aug 1, 2025 | Consulting Fee CALQUENCE · Oncology | $4,100 |
| Genzyme Corporation Feb 12, 2025 | Consulting Fee | $2,140 |
| Genentech USA, Inc. May 30, 2025 | Consulting Fee Rituxan; Polivy; Venclexta · BioOncology/Immunology | $1,605 |
| Genzyme Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $1,070 |
| AbbVie Inc. Mar 14, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $820 |
| AbbVie Inc. Jul 30, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $820 |
| E.r. Squibb & Sons, L.l.c. Aug 21, 2025 | Consulting Fee | $710 |
| AbbVie Inc. Jul 4, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $615 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL · in-kind | $413 |
| AbbVie Inc. Sep 4, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $410 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Sep 4, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $410 |
| E.r. Squibb & Sons, L.l.c. Aug 21, 2025 | Consulting Fee | $710 |
| AstraZeneca Pharmaceuticals LP Aug 1, 2025 | Consulting Fee CALQUENCE · Oncology | $4,100 |
| AbbVie Inc. Jul 30, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $820 |
| AbbVie Inc. Jul 4, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $615 |
| Genentech USA, Inc. May 30, 2025 | Consulting Fee Rituxan; Polivy; Venclexta · BioOncology/Immunology | $1,605 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL · in-kind | $413 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL · in-kind | $386 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL | $302 |
| AbbVie Inc. Mar 14, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $820 |
| Genzyme Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $1,070 |
| Genzyme Corporation Feb 12, 2025 | Consulting Fee | $2,140 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $37,250 in research payments for these studies, mostly to the institutions running them.
- A Multicentre, Open-Label, Randomized, Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator s Choice of Treatment in Adults (over 18 Years) with Chronic Lymphocytic Leukemia and Moderate to…
Acerta Pharma LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.